Non-COVID-19 Cutaneous Mucormycosis from a Plastic Surgical Perspective.

Indian J Plast Surg

Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta - The Medicity, Gurugram, Haryana, India.

Published: August 2023

 Cutaneous mucormycosis is a rare and fulminant infection associated with high mortality. Plastic surgeons come across this infection in the settings of road traffic accidents, surgical site infections, and as a secondary infection with underlying bacterial soft tissue infections. Due to this infection's rarity and aggressive course, it is essential to initiate prompt multidisciplinary management at the first presentation. With this study, we aim to present a protocol for managing the condition.  This is a retrospective observational study of patients with cutaneous mucormycosis managed at a tertiary care hospital from January 1, 2016 to November 30, 2022 excluding patients with mucormycosis who tested positive for coronavirus disease 2019.  Of 24 patients, 22 were males, and most were in the age group of 41 to 60 years. Sixteen patients survived and five out of eight deceased had comorbidities, six presented primarily without prior debridement, and six had trunk involvement.  A high index of clinical suspicion is necessary for early diagnosis and management of patients with invasive cutaneous mucormycosis. A multidisciplinary approach with appropriate medical and surgical management can improve outcomes in cases that otherwise carry a high mortality rate.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497338PMC
http://dx.doi.org/10.1055/s-0043-1771294DOI Listing

Publication Analysis

Top Keywords

cutaneous mucormycosis
12
high mortality
8
mucormycosis
5
patients
5
non-covid-19 cutaneous
4
mucormycosis plastic
4
plastic surgical
4
surgical perspective
4
perspective  cutaneous
4
 cutaneous mucormycosis
4

Similar Publications

Purpose: Mucormycosis is a rare but emerging and life-threatening infection caused by environmental mold, with a mortality rate of 30-70% despite progress in management. A better understanding could improve its management.

Method: We conducted a single-center retrospective study of all cases of mucormycosis observed over a decade at the University Hospital of Caen.

View Article and Find Full Text PDF

Combined antifungal therapy with immunostimulation for refractory cutaneous and peritoneal mucormycosis caused by Rhizopus microsporus.

Diagn Microbiol Infect Dis

December 2024

Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University of Paris Cité, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisière, France Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S 942 Mascot, Lariboisière Hospital, Paris, France; INI-CRCT Network, Nancy, France; FHU PROMICE, Paris, France. Electronic address:

Mucormycosis is a fungal infection typically affecting immunocompromised patients. Here, we report a severe case of invasive cutaneous and peritoneal mucormycosis caused by Rhizopus microsporus, successfully treated with a combination of antifungal therapy, PD-1 inhibitor, and interferon-gamma. We highlight the importance of personalized immunotherapy in refractory cases of invasive mucormycosis.

View Article and Find Full Text PDF

Background: Mucormycosis, also known as black fungus, is a rare but serious fungal infection caused by mucor that belongs to Zygomycotic species. Mucor is characterized by non-septate, irregularly wide hyphae with right-angle branching. Mucor can infect different systems of the body and manifest differently depending on the location of the infection, which includes pulmonary, gastrointestinal, rhino-cerebral, and cutaneous.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!